SCHEMBL7006715

SCHEMBL7006715

CCC(CO)Nc1nc(NCc2ccccc2)c2nc(Cl)n(C(C)C)c2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 16/20 1.00
CDK2 P24941 8/20 0.68
CDK5 Q00535 8/20 0.68
CDK7 P50613 5/20 0.68
CCNE1 P24864 5/20 0.68
CDK9 P50750 4/20 0.68
CCNA2 P20248 4/20 0.68
CCNA1 P78396 4/20 0.68
CCNH P51946 3/20 0.68
CCNB1 P14635 3/20 0.68
CSNK1D P48730 2/20 0.68
CLK2 P49760 2/20 0.68
CSNK1G2 P78368 2/20 0.68
DYRK1A Q13627 2/20 0.68
CLK4 Q9HAZ1 2/20 0.68
CSNK1G1 Q9HCP0 2/20 0.68
CACNA1B Q00975 2/20 0.68
CCNK O75909 2/20 0.68
CCNE2 O96020 2/20 0.68
CDK12 Q9NYV4 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(Rs)-Roscovitine SCHEMBL172593 0.81 CDK1 (1.00) CDK1CDK2CDK5CDK7CCNE1
SCHEMBL3445122 0.81 CDK1 (0.69) CDK1CDK2CDK5CDK7CCNE1
Seliciclib SCHEMBL94728 0.81 CDK1 (1.00) CDK1CDK2CDK5CDK7CCNE1
(S)-Roscovitine SCHEMBL2907488 0.81 CDK1 (1.00) CDK1CDK2CDK5CDK7CCNE1
SCHEMBL3444679 0.81 CDK1 (0.69) CDK1CDK2CDK5CDK7CCNE1
(Rs)-Roscovitine SCHEMBL15163619 0.81 CDK1 (1.00) CDK1CDK2CDK5CDK7CCNE1
(S)-Roscovitine SCHEMBL29415376 0.81 CDK1 (1.00) CDK1CDK2CDK5CDK7CCNE1
SCHEMBL28232483 0.79 CDK2 (0.84) CDK1CDK2CDK5CDK7CCNE1
SCHEMBL3445313 0.79 CDK2 (0.71) CDK1CDK2CDK5CDK7CCNE1
SCHEMBL17450135 0.79 CDK2 (1.00) CDK1CDK2CDK5CDK7CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191086-A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof USTAV EXPERIMENTALNI BOTANIKY AV CR 2003-10-09 US disclosed
EP-1147108-B1 SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF USTAV EX BOTAN AKADEMIE VED CE (CZ) 2003-08-13 EP disclosed
US-6552192-B1 Inhibiting cyclin dependent kinase proteins, viruses, and immunostimulation; antimitotic, antiviral, anticancinogenic, antidegenerative, immunosuppressive USTAU EXPERIMENTALNI BOTANIKY AV-CR (CZ) 2003-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191086-A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof CDK4, CDK5, CCNI CDK1 6/4885CDK2 11/4885CDK5 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.